2023-04-04 15:13:30 ET
- InflaRx ( NASDAQ: IFRX ) stock has surged 60% in Tuesday afternoon trading after the US FDA authorized the company's COVID-19 treatment Gohibic (vilobelimab).
- The Emergency Use Authorization was based on results from a phase 3 trial that showed a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in critically ill mechanically ventilated COVID patients.
- InflaRx ( IFRX ) plans on submitting a Biologics License Application to the FDA to get full approval. The company also plans on working to get the drug available in Europe.
- InflaRx ( IFRX ) noted that Gohibic is a first-in-class monoclonal anti-human complement factor C5a antibody
For further details see:
InflaRx surges 60% on FDA authorization of COVID drug vilobelimab